60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Neutral” Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report report published on Monday morning,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

60 Degrees Pharmaceuticals stock opened at $1.16 on Monday. The firm has a market cap of $2.66 million, a price-to-earnings ratio of -0.12 and a beta of 5.36. 60 Degrees Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $18.36. The firm’s 50 day moving average price is $1.09 and its two-hundred day moving average price is $0.90.

Insider Transactions at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow purchased 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the transaction, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders have purchased 66,372 shares of company stock valued at $82,410 over the last three months. Company insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.